We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer (Biobank)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01084785
Recruitment Status : Recruiting
First Posted : March 11, 2010
Last Update Posted : April 7, 2022
Maastricht University Medical Center
Information provided by (Responsible Party):
Maastricht Radiation Oncology

Brief Summary:
The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.

Condition or disease

Detailed Description:
It has already been known for a long time that cancer is a genetic disorder and that the development of the illness is a very complex interaction between genetic and surrounding factors. Also the response on therapy and the development and seriousness of side effects is stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it is not only the DNA that plays an important role but also the systems of control at protein level. At this moment a lot of questions remain to be answered because up till now the studies were of rather restricted statistic strength with frequently inconsistent dates and moreover retrospective. Major retrospective studies are necessary to distinguish the relationship between DNA/protein patterns and clinical relevant endpoints like prognosis and toxicity in which an as broad as possible patient group is being monitored. For this reason we want to take blood samples in MAASTRO clinic of all patients with lung cancer and to store it encrypted so that we can perform DNA and protein analyses in future and to correlate the results with survival and toxicity of the treatment.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic
Study Start Date : January 2003
Estimated Primary Completion Date : January 2025
Estimated Study Completion Date : January 2025

Biospecimen Retention:   Samples With DNA
whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clinic

Inclusion Criteria:

  • cancer

Exclusion Criteria:

  • not able to comply with follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01084785

Layout table for location contacts
Contact: Philippe Lambin, Prof PHD 31 (0) 088 44 55 666 philippe.lambin@maastro.nl
Contact: Dirk De Ruysscher, Prof PHD 31 (0) 088 44 55 666 dirk.deruysscher@maastro.nl

Layout table for location information
Maastricht Radiation Oncology Recruiting
Maastricht, Limburg, Netherlands
Contact: Dirk De Ruysscher, Prof PHD    31 (0) 88 44 55 666    dirk.deruysscher@maastro.nl   
Contact: Philippe Lambin, Prof PHD    31 (0) 88 44 55 666    philippe.lambin@maastro.nl   
Principal Investigator: Dirk De Ruysscher, Prof PHD         
Sponsors and Collaborators
Maastricht Radiation Oncology
Maastricht University Medical Center
Layout table for investigator information
Principal Investigator: Dirk De Ruysscher, Prof PHD CCMO
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Maastricht Radiation Oncology
ClinicalTrials.gov Identifier: NCT01084785    
Obsolete Identifiers: NCT00157352, NCT00157365, NCT00157391, NCT00157404, NCT00157417, NCT00157430, NCT00157443, NCT00157456, NCT00157469, NCT00157495, NCT00181337, NCT00181376, NCT00181389, NCT00181402, NCT00181415, NCT00181428, NCT00181441, NCT00181454, NCT00181467, NCT00181480, NCT00181493, NCT00181519, NCT01067872
Other Study ID Numbers: 08-06-23/01
First Posted: March 11, 2010    Key Record Dates
Last Update Posted: April 7, 2022
Last Verified: April 2022
Keywords provided by Maastricht Radiation Oncology: